{
  "docId": "019de073-e127-72a6-a95e-e417b3ed6013",
  "docSlug": "0a46c3e8bf46013b57087adaac7a88f4",
  "documentTitle": "Xeris Biopharma | Investor Presentation Deck | 11 slides",
  "authorId": "xeris-biopharma",
  "authorName": "Xeris Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 11,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 6,
  "notes": "The slide outlines a clinical trial structure involving two parts, with crossover periods for Part 1.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-e127-72a6-a95e-e417b3ed6013/6",
  "deckHref": "/decks/019de073-e127-72a6-a95e-e417b3ed6013",
  "deckJsonHref": "/decks/019de073-e127-72a6-a95e-e417b3ed6013.json",
  "deckAnchorHref": "/decks/019de073-e127-72a6-a95e-e417b3ed6013#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.9,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Study flow diagram showing Part 1 (crossover) and Part 2 (parallel) arms with specific dosages and group sizes.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b2ffbabd-57cf-412e-8f16-70a5486be859",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.08,
        "y": 0.8
      },
      "kind": "list",
      "text": "Mean Concentration Profile Over Time\nKey PK Parameters - Cmax, Tmax, AUCs",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d7d41c91-fc38-4548-b4eb-0df058c54c03",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.05,
        "y": 0.74
      },
      "kind": "paragraph",
      "text": "PK results based on Baseline-Adjusted T4 Concentrations to determine:",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "07f7b0f2-a218-403e-98b9-a117b481b4c4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "Phase 1 Pharmacokinetic Study Design (XP-8121-108)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "16898e13-2284-4212-86ca-300d4515d430",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "df4bd889-a94b-4b4b-85ae-49ccb42bac87",
      "evidence": "Visual representation of study arms, periods, and washout intervals.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 6,
      "from": 5,
      "beatId": "af072837-2b90-4168-8f35-e24f021b1e1f",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "The appendix methodology slides describe the product and study design.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 5,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "f2a7b48c-76f2-4134-b42d-4dd72dd13ce4",
      "evidence": "The appendix methodology and key takeaways slides present the golden circle.",
      "position": 1,
      "objective": "How does XeriSol™ Levothyroxine work and what are the benefits?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}